Company Overview of CareDx, Inc
CareDx, Inc., together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic surveillance solutions for transplant patients in North America, Europe, the Middle East, Africa, and Latin America. The company operates through two segments, CareDx and Olerup. Its commercialized testing solution includes the AlloMap heart transplant molecular test (AlloMap), a gene expression test that helps clinicians monitor and identify heart transplant recipients with stable graft function who have a low probability of moderate/severe acute cellular rejection. The company also offers Olerup SSP, a set of human leukocyte antigen typing used prior to hematopoietic ste...
3260 Bayshore Boulevard
Brisbane, CA 94005
Founded in 1998
Key Executives for CareDx, Inc
President, Chief Executive Officer & Director
Total Annual Compensation: $450.0K
Chief Operating Officer
Total Annual Compensation: $325.0K
Chief Medical Officer and Executive VP
Total Annual Compensation: $376.6K
Chief Scientific Officer
Total Annual Compensation: $327.0K
Compensation as of Fiscal Year 2016.
CareDx, Inc Key Developments
CareDx Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2017; Provides Revenue Guidance for the Full Year of 2017; Announces Goodwill Impairment for the First Quarter Ended March 31, 2017
Jun 9 17
CareDx Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported total revenue of $11,584,000 against $6,562,000 a year ago. Loss from operations was $8,544,000 against $6,569,000 a year ago. Net loss attributable to company was $5,562,000 against $9,752,000 a year ago. Basic and diluted net loss per share was $0.26 against $0.81 a year ago. Loss before income taxes was $5,892,000 against $9,752,000 a year ago. Non-GAAP net loss was $6,847,000 against $4,381,000 a year ago. Non-GAAP basic and diluted net loss per share was $0.32 against $0.37 a year ago.
For the full year of 2017, the company continues to expect revenue to be in the range of $45 million to $50 million, excluding any potential AlloSure revenue.
For the quarter, the company reported goodwill impairment of $1,958,000.
CareDx, Inc, Annual General Meeting, Jul 13, 2017
May 30 17
CareDx, Inc, Annual General Meeting, Jul 13, 2017, at 10:00 Pacific Standard Time. Location: headquarters, located at 3260 Bayshore Blvd. Brisbane California United States Agenda: To elect two Class III directors to serve until the 2020 annual meeting of stockholders or until their successors are duly elected and qualified; to ratify the appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2017; to approve the issuance of shares of the company's common stock upon the conversion or redemption of the company's 9.5% Original Issue Discount Senior Secured Debentures due February 28, 2020 without the need for any limitation or cap on issuances as required by and in accordance with NASDAQ Listing Rule 5635; and to transact such other business as may properly come before the annual meeting and any adjournments or postponements thereof.
CareDx Inc. Announces Preliminary Earnings Results for the First Quarter Ended March 31, 2017; Provides Revenue Guidance for the Full Year 2017
May 22 17
CareDx Inc. announced preliminary earnings results for the first quarter ended March 31, 2017. For the quarter, the company reported preliminary revenues were $11.4 million to $11.6 million compared with $6.6 million in the first quarter of 2016. Preliminary revenues from AlloMap tests for the three months ended March 31, 2017, were $7.7 million to $7.9 million compared with $6.5 million in the first quarter of 2016. Preliminary Olerup revenues were $3.7 million. Preliminary net loss was in the range of $6.8 million to $5.8 million, compared to net loss of $9.8 million in the first quarter of 2016. Preliminary basic and diluted net loss per share were in the range $0.32 to $0.27 in the first quarter of 2017, compared to basic and diluted net loss per share of $0.81 in the first quarter of 2016.
For the full year 2017, the company continues to expect revenue to be in the range of $45 million to $50 million, excluding any potential AlloSure revenue.
Similar Private Companies By Industry
Recent Private Companies Transactions
March 15, 2017